Relevance of long-lived CD8+T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination

Frontiers in Immunology

Volumn 3, Issue DEC, 2012, Pages

  Vasconcelos, José R ^a   Dominguez, Mariana R ^a   Araújo, Adriano F ^a   Ersching, Jonatan ^a   Tararam, Cibele A ^a   Bruna Romero, Oscar ^b   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adenovirus; CD8; Memory; Vaccines

Indexed keywords

EID: 84874279765     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00358     Document Type: Article

References (134)

1. Acierno, P. M., Schmitz, J. E., Gorgone, D. A., Sun, Y., Santra, S., Seaman, M. S., et al. (2006). Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 176,5338-5345.
2. Ahmed, R., and Akondy, R. S. (2011). Insights into human CD8+ cell memory using the yellow fever and smallpox vaccines. Immunol. Cell Biol. 89, 340-345.
3. Aidoo, M., Otten, R. A., Rodriguez, V., Sariol, C. A., Martinez, M., Kraisel-burd, E., et al. (2007). Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations. Vaccine 25, 6474-6481.
4. Akram, A., and Inman, R. D. (2012). Immunodominance: a pivotal principle in host response to viral infections. Clin. Immunol. 143, 99-115.
5. Amara, R. R.,Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. L., et al. (2001). Control of amucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
6. Angelosanto, J. M., and Wherry, E. J. (2010). Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol. Rev. 236, 167-175.
7. Bachmann, M. F., Wolint, P., Schwarz, K., Jäger, P., and Oxenius, A. (2005a). Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 175,4686-4696.
8. Bachmann, M. F., Wolint, P., Schwarz, K., and Oxenius, A. (2005b). Recall proliferation potential of memory CD8+ T cells and antiviral protection.J. Immunol. 175,4677-4685.
9. Bannard, O., Kraman, M., and Fearon, D. T. (2009). Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science 323, 505-509.
10. Barouch, D. H. (2010). Novel adenovirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS 5, 386-390.
11. Barouch, D. H., Liu, J., Li, H., Max-field, L. F., Abbink, P., Lynch, D. M., et al. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 7383, 89-93.
12. Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gor-gone, D. A., et al. (2003). Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77, 8729-8735.
13. Bassett, J. D., Yang, T. C., Bernard, D., Millar, J. B., Swift, S. L., McGray, A. J., et al. (2011). CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoi-etic antigen-presenting cells. Blood 117,1146-1155.
14. Beveridge, N. E., Price, D. A., Casazza, J. P., Pathan, A. A., Sander, C. R., Asher, T. E., et al. (2007). Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 37,3089-3100.
15. Bouillet, P., and O'Reilly, L. A. (2009). CD95, BIM and T cell homeostasis. Nat. Rev. Immunol. 9, 514-519.
16. Bruña-Romero, O., González-Aseguinolaza, G., Hafalla, J. C., Tsuji, M., and Nussenzweig, R. S. (2001). Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. U.S.A. 98, 11491-11496.
17. Casey, K. A., Fraser, K. A., Schenkel, J. M., Moran, A., Abt, M. C., Beura, L. K., et al. (2012). Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J. Immunol. 188,4866-4875.
18. Casimiro, D. R., Chen, L., Fu, T. M., Evans, R. K., Caulfield, M. J., Davies, M. E., et al. (2003). Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305-6313.
19. Casimiro, D. R., Wang, F., Schleif, W. A., Liang, X., Zhang, Z. Q., Tobery, T. W., et al. (2005). Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547-15555.
20. Cayabyab, M. J., Korioth-Schmitz, B., Sun, Y., Carville, A., Balachan-dran, H., Miura, A., et al. (2009). Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cellresponses.J. Virol. 83, 5505-5513.
21. Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., et al. (2006). Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24,417-425.
22. Chopera, D. R., Wright, J. K., Brock-man, M. A., and Brumme, Z. L. (2011). Immune-mediated attenuation of HIV-1. Future Virol. 6, 917-928.
23. Churchyard, G. J., Morgan, C., Adams, E., Hural, J., Graham, B. S., Moodie, Z., et al. (2011). A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE 6, e21225. doi: 10.1371/jour-nal.pone.0021225
24. Cockburn, I. A., Chakravarty, S., Over-street, M. G., García-Sastre, A., and Zavala, E (2008). Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J. Immunol. 180, 64-71.
25. Cox, K. S., Clair, J. H., Prokop, M. T., Sykes, K. J., Dubey, S. A., Shiver, J. H., et al. (2008). DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J. Virol. 82, 8161- 8171.
26. Cui, W., and Kaech, S. M. (2010). Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol. Rev. 236,151-166.
27. de Alencar, B. C. G., Persechini, P. M., Haolla, E A., De Oliveira, G., Sil-verio, J. C., Lannes-Vieira, J., et al. (2009). Perforin and gamma inter-feron expression are required for CD4+ and CD8+ T-Cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect. Immun. 77,4383-4395.
28. De Rosa, S. C., Thomas, E. P., Bui, J., Huang, Y., deCamp, A., Morgan, C., et al. (2011). National institute of allergy and infectious diseases HIV vaccine trials network. V-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J. Immunol. 187, 3391-3401.
29. Dominguez, M. R., Ersching, J., Lemos, R., Machado, A. V., Bruna-Romero, O., Rodrigues, M. M., et al. (2012). Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi. Vaccine 30, 2882-2891.
30. Dominguez, M. R., Silveira, E. L., de Vasconcelos, J. R., de Alencar, B. C., Machado, A. V., Bruna-Romero, O., et al. (2011). Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS ONE 6, e22011. doi: 10.1371/journal.pone.0022011
31. Dudani, R., Murali-Krishna, K., Krishnan, L., and Sad, S. (2008). IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intra-cellular bacterium. J. Immunol. 181, 1700-1709.
32. Duke, C. M., Maguire, C. A., Keefer, M. C., Federoff, H. J., Bowers, W J., and Dewhurst, S. (2007). HSV-1 ampli-con vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 25, 7410-7421.
33. Dunachie, S. J., Walther, M., Epstein, J. E., Keating, S., Berthoud, T., Andrews, L., et al. (2006). DNA prime-modified vaccinia virus Ankara boost vaccine encoding thro-mbospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium fal-ciparum sporozoite challenge. Infect. Immun. 74, 5933-5942.
34. Ellenberger, D., Otten, R. A., Li, B., Aidoo, M., Rodriguez, I. V., Sariol, C. A., et al. (2006). HIV-1 DNA/MVA vaccination reduces the per expo sure probability of infection during repeated mucosal SHIV challenges. Virology 352, 216-225.
35. Elvang, T., Christensen, J. P., Billeskov, R., Thi Kim Thanh Hoang, T., Holst, P.,Thomsen,A. R.,et al. (2009). CD4 and CD8 T cell responses to the M. tuberculosis AgS5B-TBlOA promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4, e5139. doi: 10.1371/journal.pone.0005139
36. Finn, J. D., Bassett, J., Millar, J. B., Grinshtein, N., Yang, T. C., Parsons, R., et al. (2009). Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol. 83, 12027-12036.
37. Flatz, L., Roychoudhuri, R., Honda, M., Filali-Mouhim, A., Goulet, J. P., Kettaf, N., et al. (2011). Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proc. Natl. Acad. Sci. U.S.A. 108,5724-5729.
38. Frahm, N., DeCamp, A. C., Friedrich, D. P., Carter, D. K., Defawe, O. D., Kublin, J. G., et al. (2012). Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J. Clin. Invest. 122, 359-367.
39. Freel, S. A., Lamoreaux, L., Chattopad-hyay, P. K., Saunders, K., Zarkowsky, D., Overman, R. G., et al. (2010). Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84, 4998-5006.
40. Gebhardt, T., Wakim, L. M., Eidsmo, L., Reading, P. C., Heath, W. R., and Carbone E R. (2009). Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524-530.
41. Geisbert, T. W., Bailey, M., Geisbert, J. B., Asiedu, C., Roederer, M., Grazia-Pau, M., et al. (2010). Vector choice determines immunogenic-ity and potency of genetic vaccines against Angola Marburg virus in non-human primates. J. Virol. 84, 10386-10394.
42. Gilbert, S. C., Moorthy, V. S., Andrews, L., Pathan, A. A., McConkey, S. J., Vuola, J. M., et al. (2006). Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24,4554-4561.
43. Gilbert, S. C., Schneider, J., Hannan, C. M., Hu, J. T., Plebanski, M., Sinden, R., et al. (2002). Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenovi-ral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20,1039-1045.
44. Gómez, C. E., Nájera, J. L., Krupa, M., Perdiguero, B., and Esteban, M. (2011). MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 11, 189-217.
45. Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Cebere, I., Mah-moud, A., et al. (2006). Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80, 4717-4728.
46. Green, D. R. (2008). Fas Bim boom! Immunity28, 141-143.
47. Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., et al. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527.
48. Harari, A., Bart, P. A., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., et al. (2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205, 63-77.
49. Haut, L. H., Ratcliffe, S., Pinto, A. R., and Ertl, H. (2011). Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector. J. Infect. Dis. 203, 1073-1081.
50. Helbig, C., Gentek, R., Backer, R. A., de Souza, Y., Derks, I. A., Eldering, E., et al. (2012). Notch controls the magnitude of T helper cell responses by promoting cellular longevity. Proc. Natl. Acad. Sci. U.S.A. 109, 9041-9046.
51. Hensley, L. E., Mulangu, S., Asiedu, C., Johnson, J., Honko, A. N., Stanley, D., et al. (2010). Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 6, e1000904. doi: 10.1371/jour-nal.ppat.1000904
52. Hikono, H., Kohlmeier, J. E., Taka-mura, S., Wittmer, S. T., Roberts, A. D., and Woodland, D. L. (2007). Activation phenotype, rather than central or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med. 204, 1625-1636.
53. Hoft, D. F., Blazevic, A., Stanley, J., Landry, B., Sizemore, D., Kpamegan, E., et al. (2012). A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 30, 2098-2108.
54. Hughes, P. D., Belz, G. T., Fortner, K. A., Budd, R. C., Strasser, A., and Bouillet, P. (2008). Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 28, 197-205.
55. Huster, K. M., Koffler, M., Stemberger, C., Schiemann, M., Wagner, H., and Busch, D. H. (2006). Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells. Eur. J. Immunol. 36,1453-1464.
56. Huster, K. M., Stemberger, C., Gasteiger, G., Kastenmüller, W., Drexler, I., and Busch, D. H. (2009). Cutting edge: memory CD8 T cell compartment grows in size with immuno-logical experience but nevertheless can lose function. J. Immunol. 183, 6898-6902.
57. Hutnick, N. A., Myles, D. J., Hirao, L., Scott, V L., Ferraro, B., Khan, A. S., et al. (2012). An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIV-mac251 challenge. Vaccine 30, 3202-3208.
58. Irvine, K. R., Chamberlain, R. S., Shul-man, E. P., Surman, D. R., Rosenberg, S. A., and Restifo, N. P. (1997). Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89, 1595-1601.
59. Jameson, S. C., and Masopust, D. (2009). Diversity in T cell memory: an embarrassment of riches. Immunity 31, 859-871.
60. Jaoko, W., Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., et al. (2010). Safety and immunogenicity study of mul-ticlade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 5, e12873. doi: 10.1371/journal.pone.0012873
61. Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., and Kupper, T. S. (2012). Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 483,227-231.
62. Kaufman, D. R., Bivas-Benita, M., Simmons, N. L., Miller, D., and Barouch, D. H. (2010). Route of adenovirus based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lympho cytes. J. Virol. 84, 5986-5996.
63. Keating, S. M., Bejon, P., Berthoud, T., Vuola, J. M., Todryk, S., Webster, D. P., et al. (2005). Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175, 5675-5680.
64. Kohlmeier, J. E., Reiley, W. W., Perona-Wright, G., Freeman, M. L., Yager, E. J., Connor, L. M., et al. (2011). Inflammatory chemokine receptors regulate CD8+ T cell contraction and memory generation following infection. J. Exp. Med. 208, 1621-1634.
65. Koup, R. A., Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M. C., et al. (2010). Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 5, e9015. doi: 10.1371/journal.pone.0009015
66. Kursar, M., Jnner, N., Pfeffer, K., Brinkmann, V., Kaufmann, S. H., and Mittrücker, H. W. (2008). Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Lis-teria monocytogenes. Eur. J. Immunol. 38, 127-138.
67. Lai, L., Kwa, S., Kozlowski, P. A., Mon-tefiori, D. C., Ferrari, G., Johnson, W E., et al. (2011). Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 204, 164-173.
68. Lakhashe, S. K., Velu, V., Sciaranghella, G., Siddappa, N. B., Dipasquale, J. M., Hemashettar, G., et al. (2011). Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29, 5611-5622.
69. Lasaro, M. O., and Ertl, H. C. (2009). New insights on adenovirus as vaccine vectors. Mol Ther. 17, 1333-1339.
70. Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., et al. (2006). Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312,1530-1533.
71. Li, Q., Rao, R., Vazzana, J., Goedege-buure, P., Odunsi, K., Gillanders, W., et al. (2012). Regulating mammalian target of rapamycin to tune vaccination-induced CD8+ T cell responses for tumor immunity. J. Immunol. 188,3080-3087.
72. Li, S., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Esteban, M., Palese, P., et al. (1993). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. U.S.A. 90,5214-5218.
73. Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lem-ckert, A. A., et al. (2008). Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852.
74. Mackay, L. K., Stock, A. T., Ma, J. Z., Jones, C. M., Kent, S. J., Mueller, S. N., et al. (2012). Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. U.S.A. 109, 7037-7042.
75. Magalhaes, I., Sizemore, D. R., Ahmed, R. K., Mueller, S., Wehlin, L., Scanga, C., et al. (2008). rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 3, e3790. doi: 10.1371/journal.pone.0003790
76. Martinon, F., Brochard, P., Ripaux, M., Delache, B., Aurégan, G., Vaslin, B., et al. (2008). Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Vaccine 26,532-545.
77. Martins, M. A., Wilson, N. A., Reed, J. S., Ahn, C.D., Klimentidis, Y. C., Allison, D. B., et al. (2010). T-cell correlates of vaccine efficacy after a heterolo-gous simian immunodeficiency virus challenge. J. Virol. 84, 4352-4365.
78. Masopust, D., Choo, D., Vezys, V., Wherry, E. J., Duraiswamy, J., Akondy, R., et al. (2010). Dynamic T cell migration program provides resident memory within intestinal epithelium. J. Exp. Med. 207, 553-564.
79. Masopust, D., Ha, S. J., Vezys, V., and Ahmed, R. (2006). Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177, 831-839.
80. Mattapallil, J. J., Douek, D. C., Buckler-White, A., Montefiori, D., Letvin, N. L., Nabel, G. J., et al. (2006). Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203,1533-1541.
81. McConkey, S. J., Reece, W. H., Moor-thy, V S., Webster, D., Dunachie, S., Butcher, G., et al. (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombi-nant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735.
82. McShane, H., Brookes, R., Gilbert, S. C., and Hill, A. V (2001). Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69,681-686.
83. Moore, A. C., and Hill, A. V (2004). Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143.
84. Moorthy, V S., Imoukhuede, E. B., Mil-ligan, P., Bojang, K., Keating, S., Kaye, P., et al. (2004). A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gam-bian adults. PLoS Med. 1, e33. doi: 10.1371/journal.pmed.0010033
85. Mudd, P. A., and Watkins, D. I. (2011). Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses. Curr. Opin. HIV AIDS 6, 197-201.
86. Murata, K., García-Sastre, A., Tsuji, M., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., et al. (1996). Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell. Immunol. 173,96-107.
87. Nigam, P., Earl, P. L., Americo, J. L., Sharma, S., Wyatt, L. S., Edghill-Spano, Y., et al. (2007). DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 151,73-83.
88. Nolz, J. C., and Harty, J. T. (2011). Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv. Exp. Med. Biol. 780, 69-83.
89. Peiperl, L., Morgan, C., Moodie, Z., Li, H., Russell, N., Graham, B. S., et al. (2010). Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: arandom-ized clinical trial (HVTN 054). PLoS ONE 5, e13579. doi: 10.1371/jour-nal.pone.0013579
90. Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hen-gartner, H., and Zinkernagel, R. M. (2000). FTY720 immunosuppres-sion impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164,5761-5770.
91. Pinto, A. R., Fitzgerald, J. C., Giles-Davis, W., Gao, G. P., Wilson, J. M., and Ertl, H. C. (2003). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted aden-oviral vaccine carriers. J. Immunol. 171, 6774-6779.
92. Porter, D. W., Thompson, F. M., Berthoud, T. K., Hutchings, C. L., Andrews, L., Biswas, S., et al. (2011). A human phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29, 7514-7522.
93. Pulko, V., Harris, K. J., Liu, X., Gibbons, R. M., Harrington, S. M., Krco, C. J., et al. (2011). B7-h1 expressed by activated CD8 T cells is essential for their survival. J. Immunol. 187,5606-5614.
94. Purwar, R., Campbell, J., Murphy, G., Richards, W G., Clark, R. A., and Kupper, T. S. (2011). Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS ONE 6, e16245. doi: 10.1371/jour-nal.pone.0016245
95. Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S. C., Nicosia, A., et al. (2010). Prime-boost immunization with adenovi-ral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78, 145-153.
96. Reyes-Sandoval, A., Wyllie, D. H., Bauza, K., Milicic, A., Forbes, E. K., Rollier, C. S., et al. (2011). CD8+ T effector memory cells protect against liver-stage malaria. J. Immunol. 187, 1347-1357.
97. Rice, J., Ottensmeier, C. H., and Stevenson, F. K. (2008). DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8, 108-120.
98. Rigato, P. O., De Alencar, B. C., De Vasconcelos, J. R. C., Dominguez, M. R., Araujo, A. F., Machado, A. V., et al. (2011). Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8+ T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect. Immun. 79,2120-2130.
99. Rodríguez, D., González-Aseguinolaza, G., Rodríguez, J. R., Vijayan, A., Gher-ardi, M., Rueda, P., et al. (2012). Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmod-ium. PLoS ONE 7, e34445. doi: 10.1371/journal.pone.0034445
100. Rodrigues, M., Li, S., Murata, K., Rodriguez, D., Rodriguez, J. R., Bacik, I., et al. (1994). Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153, 4636-4648.
101. Saade, F., and Petrovsky, N. (2012). Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines 11, 189-209.
102. Sadagopal, S., Amara, R. R., Kannan-ganat, S., Sharma, S., Chennareddi, L., and Robinson, H. L. (2008). Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J. Virol. 82,4149-4153.
103. Santra, S., Seaman, M. S., Xu, L., Barouch, D. H., Lord, C. I., Lifton, M. A., et al. (2005). Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in non-human primates. J. Virol. 79, 6516- 6522.
104. Schirmbeck, R., Reimann, J., Kochanek, S., and Kreppel, F. (2008). The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther. 16, 1609-1616.
105. Schmidt, N. W., and Harty, J. T. (2011). Cutting edge: attrition of Plasmod-ium-specific memory CD8 T cells results in decreased protection that is rescued by booster immunization. J. Immunol. 186,3836-3840.
106. Schneider, J., Gilbert, S. C., Blan-chard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., et al. (1998). Enhanced immunogenicity for CD8 T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402.
107. Schooley, R. T., Spritzler, J., Wang, H., Lederman, M. M., Havlir, D., Kuritzkes, D. R., et al. (2010). AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J. Infect. Dis. 202, 705-716.
108. Sedegah, M., Jones, T. R., Kaur, M., Hedstrom, R., Hobart, P., Tine, J. A., et al. (1998). Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 95, 7648-7653.
109. Selin, L. K., Lin, M. Y., Kraemer, K. A., Pardoll, D. M., Schneck, J. P., Varga, S. M., et al. (1999). Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11, 733-742.
110. Selin, L. K., Vergilis, K., Welsh, R. M., and Nahill, S. R. (1996). Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J. Exp. Med. 183, 2489-2499.
111. Sheridan, B. S., and Lefrançois, L. (2011). Regional and mucosal memory T cells. Nat. Immunol. 12, 485-491.
112. Streeck, H., and Nixon, D. E (2010). T cell immunity in acute HIV-1 infection. J. Infect. Dis. 202(Suppl. 2), S302-S308.
113. Sun, Y., Schmitz, J. E., Buzby, A. P., Barker, B. R., Rao, S. S., Xu, L., et al. (2006). Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J. Virol. 80, 10950-10956.
114. Suthar, M. S., Ramos, H. J., Brassil, M. M., Netland, J., Chappell, C. P., Blahnik, G., et al. (2012). The RIG-I-like receptor LGP2 controls CD8+ T cell survival and fitness. Immunity 37,235-248.
115. Takai, S., Sabzevari, H., Farsaci, B., Schlom, J., and Greiner, J. W. (2012). Distinct effects of saraca-tinib on memory CD8+ T cell differentiation. J. Immunol. 188, 4323- 4333.
116. Tao, D., Barba-Spaeth, G., Rai, U., Nussenzweig, V., Rice, C. M., and Nussenzweig, R. S. (2005). Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 201,201-209.
117. Tatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., et al. (2007). Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110, 1916-1923.
118. Vasconcelos, J. R., Bruña-Romero, O., Araújo, A. F., Dominguez, M. R., Ersching, J., de Alencar, B. C., et al. (2012). Pathogen-induced proapop-totic phenotype and high CD95 (Fas) expression accompany a subopti-mal CD8+ T-cell response: reversal by adenoviral vaccine. PLoS Pathog. 8, e1002699. doi: 10.1371/jour-nal.ppat.1002699
119. Vezys, V., Yates, A., Casey, K. A., Lanier, G.,Ahmed, R.,Antia,R.,et al. (2009). Memory CD8 T-cell compartment grows in size with immunological experience. Nature 457, 196-199.
120. Vijayan, A., Gómez, C. E., Espinosa, D. A., Goodman, A. G., Sanchez-Sampedro, L., Sorzano, C. O., et al. (2012). Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. J. Immunol. 188,6407-6417.
121. Vojnov, L., Bean, A. T., Peterson, E J., Chiuchiolo, M. J., Sacha, J. B., Denes, F. S., et al. (2011). DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4+ T cells, but few subdominant epitope-specific CD8+ T cells. Vaccine 29, 7483-7490.
122. Vuola, J. M., Keating, S., Webster, D. P., Berthoud, T., Dunachie, S., Gilbert, S. C., et al. (2005). Differential immunogenicity of various heterol-ogous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174, 449-455.
123. Wakim, L. M., Waithman, J., van Rooi-jen, N., Heath, W. R., and Car-bone, F. R. (2008). Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 319, 198-202.
124. Wakim, L. M., Woodward-Davis, A., and Bevan, M. J. (2010). Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl. Acad. Sci. U.S.A. 107, 17872-17879.
125. Wakim, L. M., Woodward-Davis, A., Liu, R., Hu, Y., Villadangos, J., Smyth, G., et al. (2012). The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189,3462-3471.
126. Weant, A. E., Michalek, R. D., Khan, I. U., Holbrook, B. C., Willingham, M. C., and Grayson, J. M. (2008). Apop-tosis regulators Bim and Fas function concurrently to control autoimmu-nity and CD8+ T cell contraction. Immunity 28,218-230.
127. Wiesel, M., Walton, S., Richter, K., and Oxenius, A. (2009). Virus-specific CD8 T cells: activation, differentiation and memory formation. APMIS 117,356-381.
128. Wilks, A. B., Christian, E. C., Seaman, M. S., Sircar, P., Carville, A., Gomez, C. E., et al. (2010). Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J. Immunol. 185, 7097-7106.
129. Wilson, N. A., Reed, J., Napoe, G. S., Piaskowski, S., Szymanski, A., Furlott, J., et al. (2006). Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885.
130. Winstone, N., Guimarães-Walker, A., Roberts, J., Brown, D., Loach, V., Goonetilleke, N., et al. (2009). Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur. J. Immunol. 39, 975-985.
131. Winstone, N., Wilson, A. J., Morrow, G., Boggiano, C., Chiuchiolo, M. J., Lopez, M., et al. (2011). Enhanced control of pathogenic simian immunodeficiency virus SIV-mac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.J. Virol. 85, 9578-9587.
132. Xiao, H., Peng, Y., Hong, Y., Liu, Y., Guo, Z. S., Bartlett, D. L., et al. (2011). Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J. Immunol. 187, 1788-1796.
133. Yamamoto, T., Johnson, M. J., Price, D. A., Wolinsky, D. I., Almeida, J. R., Petrovas, C., et al. (2012). Virus inhibition activity of effector memory CD8+ T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J. Virol. 86, 5877-5884.
134. Zavala, F., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Nussenzweig, R. S., and Esteban, M. (2001). A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8+ T cells. Virology 280,155-159.